Best Life Sciences Platforms and Tools Companies in Texas, United States

Instruments and devices for biomedical application

Innovating medical technologies, from development to commercialization, improving clinical outcomes. They fuse business with science, linking innovations with consumers. They focus on achieving superior clinical outcomes and producing truly innovative medical products. They form collaborative partnerships with scientists, supporting their research and bringing resulting products to the marketplace. Their model uses non-dilutive government funding to demonstrate product safety and technology feasibility. They are committed to combining rigorous processes with an accomplished staff, accelerating technology transfer and commercialization. They offer formulation development, regulatory expertise, and manufacturing capabilities. They develop products like mouth rinse, software platform, and skincare.

Developer of IVD and targets cancer cells for therapeutics. The company design a platform for the detection and treatment of many cancers. The first product of the company CyPath is a bio label with a high affinity for cancer cells. This label technology allows cancer cells to fluoresce, leading to detection.

Developer of C.elegans based assays for drug discovery. The company has used microfluidics technology for developing a benchtop screening system that conducts large-scale in vivo assays for genetic and drug screening, toxicology, and mechanistic studies. This system has an infinity chip that provides a soil-like environment to an organism where it is fed, washed and imaging is done by an infinity processor and data analysis is done by infinity code software. This platform can be used along with pharmaceuticals in food industries, nutraceuticals, cosmetics, and others.

Developer of protein-based biomaterial platform for energy, environment, and medicine. This platform utilizes the natural ability of proteins as molecular tools. The technology impacts multiple fields.

Funding rounds

• Mar 2025Grant (prize money)$220K
• Feb 2025Grant (prize money)$4M
• Feb 2025Grant (prize money)$4M
• Jan 2025Grant (prize money)$4M

Founders & team

David Howell SPresident and CEO

Investors

HHS, Military Health, America’s Seed Fund

Tech stack

WordpressMysqlPhpYoast SeoNginxRecaptcha

Developer of enzymes and a cofactor for therapeutic use. The company has an ADEPT platform, to synthesize enzymes and cofactors for therapeutic purposes. The breakthrough product of the company is Heparin production from the mucosal lining from slaughtered pig intestines to prevent blood clots.

Funding rounds

• Mar 2026Seed$75K
• Aug 2023Seed$523.2K

Founders & team

Keith KleemanCEO

Cell culture technology company advancing regenerative medicine and drug discovery. They specialize in cell-derived matrices that mimic the natural cellular environment, fostering more biologically relevant cell behavior. Their CELLvo™ technology supports stem cell expansion, cardiomyocyte maturation, and improved cell differentiation. They offer a range of cell culture products, including matrices and cells, designed to enhance research outcomes. They also provide custom pre-coating services for cell culture surfaces. Their technology facilitates predictive, cell-based assays, cardiotoxicity screening, and regenerative medicine research. They focus on innovation and collaboration to provide researchers with advanced tools for cell culture and analysis.

Funding rounds

• Feb 2025Grant (prize money)$300K
• Mar 2023Grant (prize money)$300K
• Jun 2019Series A$1.4M
• Sep 2018Grant (prize money)$143K

Founders & team

Robert HutchensPresident & CEO; Member of the Board of Directors

Investors

Targeted Technology, Metric Medical Devices, HHS, Fountainhead Investment Partners, JLABS

Developing sustained drug delivery platform for ocular diseases, improving patient outcomes. The company focuses on creating non-invasive solutions for treating eye conditions, particularly glaucoma. Their technology, the Evolute® Punctal Plug Delivery System, aims to improve patient compliance and therapeutic outcomes by automatically delivering medication over an extended period, eliminating the need for eye drops. This innovative approach addresses the need for better management of ocular disorders and seeks to enhance the quality of life for individuals with vision impairment. The company is dedicated to delivering sustained therapy in ophthalmology to treat multiple ophthalmic disorders. This is a B2C healthcare solution.

Funding rounds

• Sep 2025Seed$2.2M
• May 2019Seed$165K
• Oct 2018Seed$50K
• Oct 2014Seed$150K

Founders & team

Bob ButchofskyFounder and CEO

Tech stack

NginxModernizrJqueryGoogle Hosted LibrariesSucuri

Aptamer discovery and development services for diagnostics, therapeutics, and research. They specialize in custom aptamer solutions, offering services from initial discovery to functional testing and maturation. Their expertise includes aptamer selection, bioinformatics, affinity determination, and assay development. They provide reagents, cell culture services, and binding services. They focus on aptamer applications in drug discovery, therapeutic development, biomarker detection, and environmental testing. They offer innovative technologies like Multiplex SELEX and customized solutions to address project challenges. They aim to deliver effective aptamers for real-world applications, supporting clients through every phase of development, from needs definition to functional evaluation.

Funding rounds

• Mar 2025Grant (prize money)$1.8M
• Sep 2023Grant (prize money)$1M
• Aug 2023Grant (prize money)$289.7K
• Sep 2020Grant (prize money)$600K

Founders & team

Bill JacksonFounder and CEO

Investors

Eventi Capital Partners, Biotex, HHS, Broadpeak Ventures

Tech stack

Font AwesomeGoogle AnalyticsGoogle Font ApiHstsHttp/3Hubspot

Developing rapid, low-cost molecular diagnostics for point-of-care applications. The company focuses on creating simple-to-use technologies with high sensitivity and specificity. Their automated Sample Processing Instrument is microgravity-compatible, handling multiple samples quickly. They are building a molecular diagnostics system with features like CLIA-waved tests, lab-quality results, true sample-to-results capability, and fast turnaround time. The aim is to provide a low-cost device and cartridges, utilizing PCR or isothermal technology. This innovative approach enables accessible and efficient molecular diagnostics, impacting healthcare through advanced technology and improved patient outcomes. The company is involved in the biotechnology and medical device industry, offering solutions for molecular testing and diagnostics.

InGeneron has developed cell-based technologies for healthcare, veterinary and life science research. InGeneron’s advanced cell separation technologies enable preparation of adipose-derived regenerative cells, including stem cells, that have the potential to aid physicians and veterinarians in the treatment of a number of diseases, orthopedic injuries and cosmetic procedures

Provider of pillar/perfusion plates for 3D cell and organoid culture. These plates facilitate static and dynamic culture, enabling organoid testing, imaging, and scaled-up production. The plates are designed for ease of use and compatibility with standard laboratory equipment. Applications include drug screening and disease modeling using human organoids, such as liver and brain organoids.

Funding rounds

• Feb 2025Grant (prize money)$284.6K
• Aug 2023Grant (prize money)$284.6K
• Jul 2020Grant (prize money)$837.9K

Founders & team

Moo-Yeal LeeFounder & CEO

Investors

HHS